17,122
edits
Changes
Jump to navigation
Jump to search
HP802-247 '''{{FULLPAGENAME}}''' is an experimental spray treatment for venous leg ulcers. The potential value of this spray is that it could treat those people whose [[skin]] will not heal with conventional treatment (such as compression bandages and dressings), and for whom the only alternative option could be [[skin]] graft.<ref>{{REFweb
Wikify.
|last=
|first=
The new spray (HP802-247) consisted of a combination of donated [[skin]] cells and proteins.
The study was conducted by researchers from the {{UNI|University of Miami|UMiami}} and other institutions in the US [[United States]] and was funded by Healthpoint Biotherapeutics, a biotech company that specialises in wound care products. The study was published in the peer-reviewed medical journal ''The Lancet''.<ref>{{REFweb
|last=
|first=
}}</ref>
The new treatment is a form of cell treatment applied as a spray. It contains keratinocytes, which are the main cell type in the outer layer of the [[skin]], and fibroblasts, a cell type found in connective tissue. These cells had been grown in the laboratory and were originally derived from newborn [[foreskin ]] samples (removed during [[circumcision]]). This was a phase 2 trial that aimed to see whether the new treatment was effective and safe, and to find out the best dose to use. If the results of phase 2 trials are positive (as these trial results were) they will usually be followed by larger phase 3 trials.
{{REF}}